Your session is about to expire
← Back to Search
Immunotherapy + Chemoradiation for Cancer (CLOVER Trial)
CLOVER Trial Summary
This trial is testing a new combination of drugs to treat advanced solid tumors. It will evaluate how well the drugs work and how safe they are.
CLOVER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCLOVER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 33 Patients • NCT03007407CLOVER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have active infections like TB, hepatitis B/C, or HIV.I have an autoimmune-related syndrome caused by my cancer.My head and neck cancer is not in the mouth, voice box, throat, or below the throat and its origin is known.I have more than one primary cancer or tumors in both sides of a body part.I have or had an autoimmune or inflammatory disorder.I have never received immune therapy or cancer vaccines.I weigh more than 30 kg.My lung cancer is a mix of small cell and non-small cell types.I am fully active or can carry out light work.I have at least one tumor that can be measured and has not been treated with radiation.I know my HPV status for my throat cancer.I have cancer that has spread to my brain or spinal cord.My small cell lung cancer is in the extensive stage.
- Group 1: SCLC Arm 2
- Group 2: HNSCC Arm 1
- Group 3: NSCLC Arm 1
- Group 4: NSCLC Arm 2
- Group 5: NSCLC Arm 3
- Group 6: SCLC Arm 1
- Group 7: SCLC Arm 3
- Group 8: SCLC Arm 4
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available openings in this medical study for new participants?
"According to the latest data posted on clinicaltrials.gov, this medical trial is not presently searching for participants - it was originally published in May 2018 and last edited in September 2022. Fortunately, there are 6,005 other studies actively seeking individuals at present."
How many participants are enrolled in the current clinical trial?
"Recruitment for this trial has been terminated, as the last edit to its listing was made on September 27th 2022. However, there are currently 4061 clinical trials recruiting patients with small cell lung cancer and 1944 studies looking for participants that can be enrolled in a Tremelimumab-related investigation."
Could I qualify for participation in this research?
"This clinical trial is aiming to enroll 105 individuals, aged between 18 and 110 years old and diagnosed with small cell lung carcinoma. Furthermore, they must have not had any prior exposure to immunotherapy or therapeutic anticancer vaccines, possess a World Health Organization/Eastern Cooperative Oncology Group (WHO/ECOG) performance status of 0 or 1 as well as having at least one detectable lesion that has yet to be irradiated."
Does this medical experiment permit individuals over sixty years old to participate?
"This medical study is open to patients aged 18 and over, up until the age of 110."
Could you provide me with a summary of the research surrounding Tremelimumab?
"The initial trials of Tremelimumab date back to 1997 at the City of Hope Comprehensive Cancer Center. Since then, 2778 clinical studies have been completed with 1944 still active; a vast majority are based in Tucson, Arizona."
What is the chief therapeutic purpose for which Tremelimumab is regularly prescribed?
"Tremelimumab is a reliable treatment option for metastatic ureter urothelial carcinoma, as well as lymphoma, non-hodgkin's disease, merkel cell cancer and locally advanced cases of non-small cell lung cancer."
Has Tremelimumab obtained the seal of approval from the United States Food and Drug Administration?
"With limited evidence in support of its efficacy and safety, Tremelimumab has been tentatively assigned a score of 1."
Share this study with friends
Copy Link
Messenger